Efficacy and Safety of Second-Line Cabozantinib After IO-IO Versus IO-TKI Combination Therapy and the Impact of Reduced Starting Dose in Metastatic Renal Cell Carcinoma: A Multicenter Retrospective Study

Clinical Genitourinary Cancer · Elsevier

Аннотация

Publication date: Available online 5 November 2026 Source: Clinical Genitourinary Cancer Author(s): Hidetsugu Takahashi, Takafumi Yanagisawa, Maria Okamoto, Wataru Fukuokaya, Fumihiko Urabe, Keiichiro Mori, Shingo Nishimura, Ryoichi Maenosono, Shingo Toyoda, Takuhisa Nukaya, Seitetsu Sugiyama, Keita Tamura, Motoo Araki, Haruhito Azuma, Kazutoshi Fujita, Kiyoshi Takahara, Kazumasa Komura, Teruo Inamoto, Takahiro Kimura, JK-FOOT study group

Читать у издателя →

Похожие статьи